Week In Review: Henlius Out-Licenses Southeast Asia Rights For PD-1 Candidate In $692 Million Deal

Deals and Financings
Shanghai Henlius Biotech (HK:2696) announced a $692 million partnership with Kalbe Genexine Biologics for Southeast Asian rights to Henlius’ PD-1 checkpoint inhibitor (see story). Kalbe Genexine is a JV formed by Kalbe Farma of Ind…